RRdog, your frustration with the ATM is well understood, but those multiple alternatives for financing available to PPHM are likely more of the desert mirage than real once you walk up and try to take a drink from the oasis, LOL! Why do I say that?
Consider the recent loans that PPHM engaged. The one a year or two back involved assignment of all the intellectual assets of the company to cover a relative pittance for funding. I believe that loan has been closed and claims against PPHM intellectual property as collateral have been lifted--- just in time for PPHM to start talk of there being serious partnering discussions underway that would need unencumbered intellectual property.
The more recent loan with the two $15 million tranches was definitely better for PPHM, but PPHM had to scramble to pay the money back when it became clear that the third party error left PPHM vulnerable to not having the resources needed to pay back the loan. What would the bank get if PPHM defaulted?
Now consider how PPHM has been issuing shares through the ATM to keep funding going for several years now. If intellectual property had been parsed out to back loans over that period, perhaps PPHM would have had to forfeit maybe 20% of their intellectual property rights each time they went to the trough? The third party error set back and scramble for more borrowed funds could have left PPHM in a position where they had to yield more than half of their intellectual property rights to third parties, who could then leverage that with demand for liquidation to cover loan repayment. Retail share holders like us would perhaps be facing the opportunity to buy cheap shares but those shares would only be mated against a small fraction of the real value of the company.
Is that what you meant when you suggest there were alternatives? Maybe you meant partnering could have been bought cheap a couple years back. The end result would be the same as if the intellectual tech was being called due to delayed FDA approval and delivery of product.
My view is that you are doing Mr. Lyttle a disservice by assigning mirage value to funding alternatives that would have swiped intellectual rights out from under retail share holder ownership. PPHM has issued a lot more shares but I can cost average along with the ATM ratio and preserve a better proportionate standing for post FDA Bavi approval value than if the tech rights had been parsed out for survival funding, leaving a trail in the desert over the last five years.
Best wishes and IMO.
KT